Serum C-peptide as an indicator of metabolic syndrome in non-diabetic adults: a population-based study
Metabolic syndrome (MetS) and elevated C-peptide both reflect insulin resistance and increased cardiometabolic risk. We assessed whether fasting serum C-peptide can serve as an indicator of MetS in non-diabetic adults from the general population. We analyzed 4,072 adults aged 20–74 years without diabetes from a predominantly white Caucasian population participating in the Healthy Finland 2023 health examination survey. We evaluated the ability of C-peptide to discriminate MetS using receiver operating characteristic (ROC) analyses and identified optimal cut-offs using the Youden index. We compared C-peptide with glycated hemoglobin (HbA1c), high-sensitivity C-reactive protein (hs-CRP), and alanine aminotransferase (ALT), and examined performance separately in obese and non-obese participants. In the full sample, C-peptide discriminated MetS well, with AUCs of 0.80–0.81 across sexes and MetS definitions. Using the International Diabetes Federation (IDF) definition, optimal cut-offs were ≥ 0.66 nmol/L for men and ≥ 0.63 nmol/L for women (sensitivities 72% and 70%; specificities 75% and 76%). C-peptide outperformed HbA1c, ALT, and hs-CRP ( p < 0.05), suggesting its potential as a simple biomarker for early identification of MetS. Discrimination was modestly lower in non-obese participants (AUCs 0.75–0.77 across definitions) and further attenuated in obese participants (AUC 0.73–0.75 across definitions). C-peptide remained the best-performing marker in non-obese participants, whereas among obese participants its performance was comparable to HbA1c. The optimal cut-offs yielded high negative predictive values (84–87%) among non-obese participants, whereas positive predictive values were highest (79–90%) among obese participants. Fasting C-peptide is a promising screening indicator of MetS in non-diabetic adults. It outperformed several commonly used biomarkers and showed good discrimination across sexes and MetS definitions, although further studies are needed to establish its role in clinical practice.
Authors
- Susanna Aspholm
- Ilkka Vauhkonen (ORCID: https://orcid.org/0009-0001-6785-0515)
- Tero T Saukkonen (ORCID: https://orcid.org/0009-0003-5133-721X)
- Tarja Palosaari (ORCID: https://orcid.org/0000-0002-9295-3516)
- Hannu Vessari (ORCID: https://orcid.org/0009-0001-7367-4773)
- Linda Mustelin (ORCID: https://orcid.org/0000-0002-6935-3096)
- Annamari Lundqvist (ORCID: https://orcid.org/0000-0002-0262-8585)
- Tuija Jääskeläinen (ORCID: https://orcid.org/0000-0001-6263-2298)
- Aku Ojanen (ORCID: https://orcid.org/0009-0000-8378-5541)
Institutions
- Finnish Institute for Health and Welfare (FI)
- Novo Nordisk (Finland) (FI)
Publication Details
- Journal
- Diabetology & Metabolic Syndrome
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1186/s13098-026-02344-4
- Primary Topic
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Type
- article
- Field-Weighted Citation Impact
- 0.00